StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Pluvicto (lutetium Lu 177 vipivotide tetraxetan by Quarter

Pluvicto (lutetium Lu 177 vipivotide tetraxetan — PSMA radioligand therapy for mCRPC) ($M)

QuarterlyAnnual

Novartis Pluvicto (lutetium Lu 177 vipivotide tetraxetan: $674M in Q3 2026, up 19.5% from a year earlier. That is the highest of the 19 quarters on record here.

Latest, Q3 2026
674
Period ended Sep 30, 2026
Change on a year earlier
+19.5%
564 in Q3 2025
History
19 quarters
Since Q1 2022
Sources
15
Documents cited below

Where the Q3 2026 figure comes from

“|| Pluvicto | 674 | 564 | 20 | 20”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPluvicto (lutetium Lu 177 vipivotide tetraxetan — PSMA radioligand therapy for mCRPC) ($M)Year on yearSource
Q3 2026Sep 30, 2026674+19.5%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026651+43.4%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026642+73.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025605+72.4%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025564+46.1%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025454+31.6%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025371+19.7%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024351+28.6%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024386+50.8%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024345+43.8%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024310+46.9%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023273+52.5%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023256+220.0%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023240+2,300.0%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023211+10,450.0%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022179–Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up pluvicto (lutetium Lu 177 vipivotide tetraxetan

Cite this data

StockData. (2026). Novartis Pluvicto (lutetium Lu 177 vipivotide tetraxetan ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-pluvicto

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.